Replies to post #6001 on Momenta Pharmaceuticals, Inc. (MNTA)

[orangeone]

GrthGd and Dew, if AW is unwilling to launch at risk, how about a Teva-AW deal to launch the AW product where Teva shares indemnification and benefits?

We assume that a 3rd generic will trigger a price war and then a Sanofi AG. However I'm sure we can find examples where a 3 member situation did not cause collapse of the price.

A T-AW seems farfetched to me since T and AW must be competitors, but anways, just to throw it out there...

[DewDiligence]

I had asked about Amphastar's complaint [against the FDA], not their motion…

Sorry about that. Amphastar’s (amended) 38-page Complaint filed on 4/25/11 is at #msg-62543266. Further, #msg-61001695 has the FDA’s 48-page Memorandum of 2/2/11 to dismiss Amphastar’s suit. The above and the document in #msg-60610139 ought to tell you what you want to know. Regards, Dew